Top Markets
Coin of the day
Mustang Bio, Inc. Mustang Bio, Inc.

Mustang Bio, Inc.

MBIO
Rank in Stocks #35075
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Share Price
$0.594
Last synced: 2026-08-14
Market Cap
$4.50M
Change (1 day)
0.00%
Change (1 year)
-66.44%
Country
US
Trade Mustang Bio, Inc. (MBIO)

Category

P/B ratio for Mustang Bio, Inc. (MBIO)
P/B ratio as of 2026 TTM: 0
According to Mustang Bio, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Mustang Bio, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE